Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc.

BIO-B · New York Stock Exchange

Bio-Rad Laboratories, Inc. (BIO-B) is a Medical devices company in the Healthcare sector, listed on New York Stock Exchange. This page provides the complete earnings calendar, dividend schedule, and financial data for Bio-Rad Laboratories, Inc. in 2026. The next earnings report is expected on October 22, 2026.

Earnings calendar

Next earnings date

22 Oct 2026

In 63 days

EPS estimate

2.38

Revenue estimate

651.1M

Past earnings

04 Aug 2026
EPS actual
2.62 (+49.9%)
estimate 1.75
Revenue actual
651.0M (+4.3%)
estimate 624.0M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
30 Apr 2026
EPS actual
1.89 (-4.2%)
estimate 1.97
Revenue actual
592.1M (+0.4%)
estimate 589.9M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
12 Feb 2026
EPS actual
2.51 (-7.3%)
estimate 2.71
Revenue actual
693.2M (+0.6%)
estimate 688.8M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Beat Miss usd

Latest earnings analysis

Bio-Rad Laboratories beat consensus estimates in its latest earnings report, with EPS of $2.62 coming in 49.9% above expectations and revenue of $651 million exceeding estimates by 4.3%. In the previous report, EPS missed estimates while revenue came in ahead of expectations.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Bio-Rad Laboratories, Inc. creates, manufactures, and markets products essential for life science research and clinical diagnostics. Its operations span globally, covering territories such as the United States, Europe, Asia, Canada, and Latin America. The company's business is organized into two main divisions: Life Science and Clinical Diagnostics. The Life Science division develops and provides a comprehensive array of reagents, laboratory apparatus, and instruments. These are vital for various applications, including scientific research methodologies, biopharmaceutical production processes, and food quality testing. This segment dedicates its efforts to key areas within the life sciences, such as proteomics, genomics, biopharmaceutical development, cellular biology, and ensuring food safety. Its diverse clientele includes academic institutions (universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology researchers, and both food producers and testing laboratories. Conversely, the Clinical Diagnostics division specializes in designing, producing, selling, and supporting diagnostic test systems, informatics solutions, test kits, and specific quality control measures for clinical laboratories. This segment furnishes reagents, instrumentation, and software precisely tailored to address particular requirements within the in vitro diagnostics market. Its products are utilized by reference laboratories, hospital labs, state-operated newborn screening facilities, physicians' private offices, and blood transfusion centers. Furthermore, Bio-Rad offers systems and products designed for separating intricate chemical and biological substances, as well as for identifying, analyzing, and purifying their individual components. The company distributes its offerings through a multi-channel approach, leveraging both its direct sales force and a network of distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was established in 1952 and its corporate headquarters are located in Hercules, California.

Sector
Healthcare
Industry
Medical devices
Country
United States
Exchange
New York Stock Exchange
CEO
Norman D. Schwartz
Employees
7,450
IPO date
21 Sep 1999
ISIN
US0905721082
Website
bio-rad.com

Frequently asked questions

When does Bio-Rad Laboratories, Inc. (BIO-B) next report earnings?

Bio-Rad Laboratories, Inc. (BIO-B) is scheduled to report earnings on October 22, 2026.

What was Bio-Rad Laboratories, Inc.'s most recent earnings date?

Bio-Rad Laboratories, Inc. (BIO-B) last reported earnings on August 4, 2026.

Where is Bio-Rad Laboratories, Inc. stock listed?

Bio-Rad Laboratories, Inc. (BIO-B) is listed on New York Stock Exchange.